Dr Reddy’s Laboratories on Monday said the European Commission has granted marketing authorisation for its biosimilar to ...

Dr. Reddy's Laboratories has achieved a significant regulatory win with the European Commission approving AVT03, its ...

Xenographic Materials Show Positive Outcomes for Peri-Implantitis Treatment "The mesh technique with xenogenic bone substitute and collagen matrix e?ectively manages a severe peri-implantitis case.

Dr Reddy''s gets EU nod for AVT03, a biosimilar of Prolia (denosumab) and Xgeva, used to treat osteoporosis and prevent bone complications.

Pharma maker Dr. Reddy’s Laboratories Ltd. today announced that the European Commission (EC) has granted marketing authorization for AVT03, a biosimilar of Prolia (denosumab) and Xgeva (denosumab).

Dr Reddys Laboratories announced that the European Commission (EC) has granted marketing authorization for AVT03, a biosimilar of Prolia (denosumab) and Xgeva (denosumab).

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Analysis of human samples and mouse models shows inflammasome signaling drives bone resorption in males but not females, ...

Dr. Reddy’s secures European Commission approval for AVT03, a biosimilar of Prolia and Xgeva, enhancing its market presence.

The FDA has approved Osvyrti (denosumab-desu), a biosimilar to Prolia (denosumab), and Jubereq (denosumab-desu), a biosimilar to Xgeva (denosumab).

If you’re considering tooth replacement in Elgin, you’ll find that dental implants stand as the gold standard. These implants ...